Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06736262 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06736262 · ClinicalTrials.gov record · last posted 2026-08-06

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

Name: A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials — clinical trial record (NCT06736262)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusTerminated

PhasePhase 2

SponsorJasper Therapeutics, Inc.

Started2024-11-26

View on ClinicalTrials.gov ↗

Why the trial stopped

Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns.

from the ClinicalTrials.gov record

Phase 2, open-label, extension study to evaluate the long-term safety, clinical activity, and pharmacodynamics of briquilimab in participants previously enrolled in a Jasper sponsored CU clinical trial.

Protocol amendment history 3 changes detected by DataLookout

2026-08-07

Trial terminated

2026-08-07

Trial terminated: Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns.

2026-08-07

Completion moved earlier: 2026-09-30 → 2026-07-21

Trial Details

NCT Number	NCT06736262
Lead Sponsor	Jasper Therapeutics, Inc.
Conditions	Urticaria Chronic
Enrollment	67 participants
Start Date	2024-11-26
Primary Completion	2026-07-21 (estimated)
Study Completion	2026-07-21 (estimated)
Updated on ClinicalTrials.gov	2026-08-06